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Background: Few data exist on a possible benign form
of neuromyelitis optica (NMO).
Objectives: To identify NMO with a good outcome
(go-NMO) among a large population of patients and to de-
scribe demographic and clinical variables associated with
go-NMO vs standard NMO and benignmultiple sclerosis.
Design: Observational retrospective multicenter study.
Setting: Twenty-five medical centers in metropolitan
France (MF) and 3 medical centers in the French West
Indies (FWI).
Patients: A total of 175 patients with NMO were ret-
rospectively analyzed from 2 cohorts: 125 in MF and 50
patients of nonwhite race/ethnicity in the FWI. Patients
in MF fulfilled the 2006 NMO criteria, whereas patients
in the FWI fulfilled the 1999 or 2006NMO criteria. Neu-
romyelitis optica and multiple sclerosis databases were
reviewed, and patients with a score of 3 or lower on the
Expanded Disability Status Scale after a 10-year fol-
low-up period were considered to have go-NMO.
Main Outcome Measures: Clinical, laboratory, and
magnetic resonance imaging data and course of disability.
Results: In MF, go-NMO was observed in 11 patients,
including 3 untreated patients. In the FWI, NMO was
severe because of disability related to optic neuritis. Com-
pared with standard NMO, go-NMOwas associated with
a lower annualized relapse rate (0.3 vs 1.0, P .01), and
8 of 11 patients with go-NMO showed complete regres-
sion of myelitis on magnetic resonance imaging during
the disease course. Three patients experienced a dis-
abling attack of NMO after 15 years of follow-up. A good
outcome occurred less frequently among patients with
NMO than among patients withmultiple sclerosis (12.0%
vs 22.4%, P=.03).
Conclusions: Among patients in MF, go-NMO occurs
rarely. However, because a disabling attack may occur
after a long follow-up period, a benign form of NMO can-
not be defined.
Arch Neurol. 2011;68(7):918-924
N EUROMYELITIS OPTICA(NMO) is a relapsing anddisabling autoimmunedisease of the central ner-vous system, character-
ized by severe optic neuritis and exten-
sive myelitis. A direct consequence of
NMO is disability, including complete vi-
sion loss or paraplegia, which may be le-
thal in 2.9% to 25% of patients, mainly
through brainstem involvement.1-5 Optic
neuritis is initially followed by severe re-
sidual vision loss (visual acuity [VA],0.1
minutes of arc [corresponding to 20/200
on Snellen visual acuity charts]) in 30%
of patients descended from nonwhite
populations and in 22% of patients de-
scended from the white population.6 Af-
ter a first episode of myelitis, ambulation
is limited to 500m, corresponding to a re-
sidual Expanded Disability Status Scale
(EDSS) score of 4 or higher, in 37.3% of
patients.2 These data argue for develop-
ment of severe disabling inflammatory dis-
ease in the absence of immunosuppres-
sive therapies among patients with NMO.
Despite the putative severity of NMO,
there are rare reports of a benign course
in patients withNMO.7-9 Such patients de-
veloped NMO secondary to celiac dis-
ease7 or dengue infection.9 In a third case
report, NMO was observed in a patient
without evidence of systemic autoim-
mune or infectious disease.8 These re-
ported cases fulfilled the 2006 diagnostic
criteria for NMO.10 Cohort investiga-
tions that included more than 30 pa-
tients with NMO have not estimated the
proportion of patients with good out-
come NMO (go-NMO) (ie, those with a
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score of 3 on the EDSS after a 10-year follow-up pe-
riod). Evaluation of disability in these cohorts suggests
that the disease may be less severe among patients of
white3,5,11 vs nonwhite1,4 race/ethnicity.
We analyzed 2 NMO cohorts, one in metropolitan
France (MF)with 125 patients and the other in the French
West Indies (FWI) with 50 patients of nonwhite race/
ethnicity, to identify patients with go-NMO.We further
describe demographic and clinical variables associated
with go-NMOvs standardNMOand benignmultiple scle-
rosis (MS) in these geographic areas to develop hypoth-
eses about benign inflammatory disease of the central ner-
vous system.
METHODS
Weperformed an observational retrospectivemulticenter study
of NMO in France, including MF and the FWI. Data were col-
lected from September 1, 2007, through September 1, 2010,
corresponding to the end point of the study. InMF, 25 tertiary
hospital centers recruited 200 patients with a suggested diag-
nosis of NMO; 125 of these fulfilled the 2006NMO criteria and
were included in the study. Data derived from this cohort have
been published elsewhere.2 In the FWI, 3 tertiary hospital cen-
ters recruited 76 patients with a suggested diagnosis of NMO;
50 of these were included in the study (26 fulfilled the 1999
NMO criteria and 24 fulfilled the 2006 NMO criteria). Selec-
tion of patients withNMO for the study is shown in Figure1A.
Selection of patients with benign MS for the study is shown in
Figure 1B. Data were derived fromhospital medical records and
from a clinical information questionnaire specifically de-
signed for NMO. If needed, additional data were obtained from
the participating centers by e-mail or by telephone. All datawere
entered in the European Database for Multiple Sclerosis, re-
cently modified to include NMO.12 In MF, MS data were ob-
tained from the database for Alsace, a representative French re-
gion. In the FWI, MS data were obtained from the geographic
Caribbean database. Data confidentiality and security were en-
sured consistent with recommendations of the French data pro-
tection authority (Commission Nationale de l’Informatique et
des Liberte´s), which also approved the study.
Assessed for each patient with NMO were demographic
data, medical history, treatment, laboratory test results, neu-
roimaging data, and key episodes in the course of NMO (re-
lapses and successive disability score dates). In patients with
go-NMO, initial spinal cord magnetic resonance (MR)
imaging was performed a mean (SD) of 7.8 (6.5) years after
disease onset, 4.8 (4.1) years after the first episode of myelitis.
Imaging was performed immediately after the first episode of
myelitis in patients 1, 2, 3, and 5 (Table 1). Initial brain MR
imaging was performed a mean (SD) of 7.3 (6.2) years after
disease onset and was classified as normal in the presence of
criteria by Paty et al13 or by Barkhof et al14 or as abnormal in
the absence of those criteria. Serum samples from 111 patients
in MF and from 24 patients in the FWI were tested for NMO-
IgG with an indirect immunofluorescence assay on a substrate
of adult rat cerebellum and midbrain using a previously
described technique.15,16 Among the MF cohort of patients
with go-NMO in whom the immunofluorescence assay was
negative (patients 1, 2, 3, and 11), anti–aquaporin 4 antibody
detection was performed using a routinely used cell-based
assay with aquaporin 4–transfected cells.17 For the other
patients, the NMO-IgG test was unavailable at NMO onset
and was not necessary to diagnose NMO according to the
1999 or 2006 criteria. Residual disability was assessed during
at least 6 months using EDSS score and VA. An EDSS score of
3 corresponded to benign MS, and an EDSS score of 2
reflected better vision. Visual acuity was included in the
vision variable of the EDSS score.18 An EDSS score of 3 was
compatible with a maximum VA of 0.1 or less (20/200 Snel-
len) in the worse eye, and an EDSS score of 2 indicated a large
scotoma or a maximum VA of 0.33 to 0.2 (20/60 to 20/100
Snellen) in the worse eye.
Comparisons of categorical data were performed using 2
test. Comparisons of quantitative data were conducted using
Mann-Whitney test. Kaplan-Meier technique was used to es-
timate time to the second episode and time to initial treat-
ment. Survival curves were compared using log-rank test. Two-
A BFWI NMO Cohort
76 Patients with suspected NMO
5 Patients with 
isolated ON 
or LETM and 
NMO-lgG
21 Patients with 
opticospinal 
form of MS
Patients with NMO 
24 With 2006 criteria
26 With 1999 criteria
MF NMO Cohort
200 Patients with suspected NMO
30 Patients with 
isolated ON 
or LETM and 
NMO-lgG
45 Patients with 
opticospinal 
form of MS
Patients with NMO
125 With 2006 criteria
Follow-up and disability
35 With severe residual
 vision loss (VA ≤0.1)
20 With severe residual
 motor deficit (MRC ≤1)
24 ≥10 y
 0 EDSS ≤3
0 ≥20 y
Follow-up and EDSS scores
41 ≥10 y
11 EDSS ≤3
9 EDSS ≤2
19 ≥15 y
6 EDSS ≤3
4 EDSS ≤2
9 ≥20 y
0 EDSS ≤3
FWI MS Cohort
246 Patients with MS
Follow-up and EDSS scores
139 ≥10 y
27 EDSS ≤3
19 EDSS ≤2
30 ≥20 y
0 EDSS ≤3
Alsace MS Cohort
1691 Patients with MS
Follow-up and EDSS scores
869 ≥10 y
232 EDSS ≤3
170 EDSS ≤2
386 ≥20 y
63 EDSS ≤3
44 EDSS ≤2
Figure 1. Selection of patients with neuromyelitis optica (NMO) (A) and with multiple sclerosis (MS) (B) in the French West Indies (FWI) and in metropolitan
France (MF). A, Patients with NMO were analyzed for a good outcome based on the follow-up period and the level of disability (Expanded Disability Status Scale
[EDSS] score, visual acuity [VA], and Medical Research Council [MRC] score). B, Patients with MS were selected for a benign form based on the follow-up period
and the level of disability (EDSS score). In MF, MS data were obtained from the database for Alsace, a representative French region. ON indicates optic neuritis;
LETM, longitudinal extensive transverse myelitis.
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sided P .05was considered statistically significant. All analyses
were performed using commercially available statistical soft-
ware (SPSS for Windows, version 14.0; SPSS Inc, Chicago,
Illinois).
RESULTS
PATIENTS WITH go-NMO
Good-outcome NMOwas observed in 11 patients, all of
whom were in the MF cohort (Figure 1A). When 33 pa-
tients with an unknown long-term clinical course (ie,
10 years’ follow-up and EDSS score of 3) were ex-
cluded, 11 of 92 patients with go-NMO represented
12.0% of the NMO cohort. Table 1 gives individual
demographic and clinical characteristics of 11 patients
with go-NMO. The first episode of myelitis was charac-
terized by an isolated sensitive symptom in 5 patients
and by a sensorimotor deficit in 6 patients (5 with
sphincter impairment). After intravenous cortico-
therapy, recovery from myelitis was complete in 5 pa-
tients, including 3 patients with myelitis at NMO onset.
The initial episode of clinical optic neuritis was bilateral
in 1 patient. Visual acuity was 0.1 or worse (20/200
Snellen) in 6 patients, and the mean VAwas 0.2 (20/100
Snellen) in the disabled eye. After intravenous cortico-
therapy, recovery from optic neuritis was complete in 9
patients. After a mean (SD) follow-up period of 16.4
(3.9) years, the course of NMO was relapsing-remitting
in 10 patients and monophasic in patient 8, who was
lost to follow-up because of suicide 11.7 years after dis-
ease onset. Using an EDSS cutoff score of 2, patients 10
and 11 were not considered to have go-NMO. At the
end of the follow-up period, patient 3 had an EDSS
score of 7 because of severe myelitis, and patients 6 and
7 had EDSS scores of 4.5 and 5, respectively, because of
combined severe VA loss and myelitis. Residual VA of
0.1 or worse (20/200 Snellen) in 1 eye was observed
in patients 7 and 8, but the mean VAs among the entire
go-NMO cohort at the end of the follow-up period were
0.8 (20/25 Snellen) in both eyes.
Longitudinal extensive transverse myelitis was ob-
served a mean (SD) of 9.7 (5.8) years after NMO onset
and a mean (SD) of 5.8 (4.3) years after the first episode
of myelitis and was observed in 7 patients on initial spi-
nal cordMR imaging. Patient 8 was free of extensive my-
elitis at the end of the follow-up period. Apparent com-
plete regression of myelitis (Figure 2) was observed in
8 of 11 patients with go-NMO.
In the FWI cohort, no go-NMO was observed. Most
patients had severe optic neuritis with residual VA of 0.1
or worse (20.200 Snellen), despite immunosuppres-
sive therapy (Figure 1A).
DEMOGRAPHIC AND CLINICAL
VARIABLES ASSOCIATED WITH
NMO VS BENIGN MS
Demographic and clinical data associated with NMO
vs benign MS are summarized in Table 2. Excluding
demographic data (higher ratios of female to male
patients and nonwhite to white races/ethnicities in the
FWI), disease-related characteristics of standard NMO
were similar in the FWI and MF cohorts and allow a
comparison between go-NMO and standard NMO.
Compared with standard NMO, go-NMO was associ-
ated with a lower annualized relapse rate and demon-
strated a trend to delayed time from onset to a second
episode. Whereas patients with standard NMO were
often treated with immunosuppression, 3 patients
with go-NMO required no treatment, and 2 patients
with go-NMO needed only immunomodulatory
therapy.
A lower percentage of patients having NMO experi-
enced a good outcome of the disease compared with pa-
tients having benign MS in Alsace (12.0% vs 22.4%,
P= .03). Except for a predominance of nonwhite pa-
tients in the FWI cohort, demographic and clinical char-
acteristics of patients with benign MS were identical in
Alsace and in the FWI. Similar results were noted when
the cutoff for go-NMO was an EDSS score of 2 or lower.
Table 1. Demographic and Clinical Characteristics of Patients Having Neuromyelitis Optica (NMO) With a Good Outcome
Patient No./Sex/
Race/Ethnicity/
Age at Onset, y/
Follow-up, y
Topography
of First
Attack
Opticospinal
Interval, mo
First
Interattack
Interval, mo
Annualized
Relapse
Rate,
Mean NMO-IgG
Cerebrospinal
Fluid,
OCB/WBC
Count,
Cells/mm3
Abnormal Spinal
MR Imaging,
No. of Lesions/
Location of
LETM
First Brain
MR Imaging,
No. of
Lesionsa Treatment
1/F/W/17.0/15.2 ON 22 22 0.7  /0 1/CT 0 Interferon
2/M/W/51.2/14.3 SC 4 4 0.4 − −/29 1/CT 1 Azathioprine
3/M/W/27.4/16.4 SC 108 108 0.2 − /0 2/C 0 . . .
4/M/W/37.8/19.2 ON 48 36 0.4 − −/5 1/C 0 Interferon, glatiramer acetate
5/F/W/20.2/15.3 ON 96 24 0.3 − −/3 3/C, T 1 . . .
6/F/W/24.8/25.4 ON 120 60 0.3  −/0 2/C, T 0 Interferon, cyclophosphamide
7/M/A/14.7/18.2 ON 75 75 0.3  −/128 1/CT 0 Cyclophosphamide
8/F/W/29.8/11.4 SC 119 119 0.2  /16 1/. . . 0 . . .
9/F/B/35.5/14.3 ON 48 12 0.5  /4 1/C 0 Interferon, mycophenolate mofetil
10/F/W/52.3/13.7 ON 3 3 0.2 − −/5 1/C 0 Azathioprine
11/F/W/36.7/16.3 ON 48 48 0.4  −/12 1/T 0 Cyclophosphamide
Abbreviations: A, Asian; C, cervical; CT, cervicothoracic; ellipsis, not applicable; LETM, longitudinal extensive transverse myelitis; MR, magnetic resonance;
OCB, oligoclonal bands; ON, optic nerve; SC, spinal cord; T, thoracic; WBC, white blood cell; , positive; −, negative.
SI conversion factor: To convert white blood cell count to 109/L, multiply by 0.001.
aFor criteria by Paty et al13/by Barkhof et al,14 all results were negative/negative.
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COMMENT
Our study found go-NMO in 12.0% of patients among
the MF NMO cohort. No patients in the FWI NMO co-
hort had a good outcome because of severe optic neuri-
tis among this population. Compared with patients hav-
ing standardNMO, patients having go-NMOhad a lower
annualized relapse rate, and complete regression of my-
elitis on spinal cordMR imaging was observed in 8 of 11
patients with go-NMO.
Based on our results, it is difficult to conclude that a
benign formofNMOexists. First, the term benign is based
on an assessment of the natural history of the disease,
whereas only 3 patients in our cohort with go-NMOwere
untreated. Second, the expression “benign form” im-
plies a permanent condition, whereas patients withNMO
may have a good outcome for many years and then have
a disabling attack, as observed in 3 patients after 15 years
of follow-up.
To date, the so-called benign form of NMO has been
described only in case reports. Patients with opticospi-
nal demyelination secondary to celiac disease or dengue
infection dramatically improved after causative treat-
ment and a short course of corticotherapy.7,9 Primary be-
nign NMO has been described in a patient with optico-
spinal demyelination, longitudinal extensive transverse
myelitis, and normal brainMR imaging.8 The disease was
characterized by a 6-year interval between the first 2 at-
tacks and by marked swelling of a cervical lesion, which
was initially suggestive of a low-grade tumor. The pa-
tient responded to corticotherapy and experienced pro-
gressive improvement after a few months. Six years af-
ter this event, spinal cordMR imaging showed complete
regression of the initial lesion. This is in accord with our
description of go-NMO, including spontaneous improve-
ment, regressive myelitis, and a low annualized relapse
rate. In contrast, clinical predictors of death among the
FWI cohort with NMO included a high frequency of epi-
sodes during the first year of disease, blindness or sphinc-
ter signs at onset, and lack of recovery after the first attack.1
Among theMF cohort, independent risk factors for EDSS
scores of 4, 6, and 7 were not identified, but a large num-
ber of lesions on brain MR imaging during the disease
course of NMOmay predict a VA outcome of 0.1 orworse
(20/200 Snellen).2
Results of this study suggest some possible explana-
tions for low disability among patients with NMO. The
most important of these relate to the low annualized re-
lapse rate and the complete regression of myelitis onMR
imaging in 8 of 11 patients with go-NMO. These obser-
vations indicate that disability may be exclusively linked
to relapses in NMO, without progressive aggravation of
disability between relapses. The findings underline ama-
jor difference in the pathophysiological processes be-
tweenNMOandMS, inwhich a progressive course is com-
mon.2,19 Regression of myelitis on MR imaging in
inflammatory demyelinating diseases of the central ner-
vous system has been described in acute disseminated
B A T2 TSE T2 TSE STIR
1
2
3
4
1
2
3
4
Figure 2. Apparent regression of spinal cord magnetic resonance imaging hypersignal during the follow-up period in patient 4 (Table 1) having neuromyelitis
optica with a good outcome. A, Longitudinal extensive transverse myelitis was diagnosed on a longitudinal section of a 0.5-T T2-weighted turbo spin-echo
sequence (TSE/M) in 1999 (left). Transverse sections of the lesions at different levels confirmed extensive transverse myelitis, with a length of 3 or more vertebral
segments (right). B, Longitudinal section on a 1.5-T T2-weighted TSE/M (left) and a short tau inversion recovery (STIR) sequence (right) in 2004 showed
complete regression of myelitis.
ARCH NEUROL /VOL 68 (NO. 7), JULY 2011 WWW.ARCHNEUROL.COM
921
©2011 American Medical Association. All rights reserved.
Downloaded From: http://archneur.jamanetwork.com/ by a University of St. Andrews Library User  on 05/18/2015
encephalomyelitis and in the pseudotumoral formofMS.20
Such observations are uncommon in classic MS, what-
ever the course of the disease. InNMO, this point is poorly
documented, but reported cases demonstrate thatmarked
swelling in myelitis can shrink after high-dose cortico-
therapy.8,21 In a study by Cassinotto et al21 that included
17 patients with NMO, complete regression was ob-
served in only 2 patients after a 26-month follow-up pe-
riod. In most cases, these spinal cord lesions progress to
atrophy and necrosis, leading to syrinxlike cavities on T1-
weighted images. From a pathological point of view, it
would be relevant to correlate transient myelitis in NMO
with the presence of NMO-IgG, which can appear and
disappear during the course of the disease.22 Involve-
ment of immunosuppressive therapies in this transitory
detectionwas not demonstrated in a large prospective fol-
low-up study,2 but our data show that the phenomenon
can occur without any treatment.
Good-outcome NMOwas observed in the MF cohort
but not in the FWI cohort. Differences in genetic back-
grounds may be a key factor in accounting for these re-
sults, as suggested by the low proportion of nonwhite pa-
tients with go-NMO in the MF cohort. Despite
immunosuppressive therapy, themedian time in the FWI
cohort fromNMOonset to an EDSS score of 3 was 1 year,
and death occurred in 25% of patients.1 In other NMO
cohorts of primarily white race/ethnicity, percentages of
patients with NMO-related death were as follows: 2.9%
in a Mexican cohort,4 3.2% in an MF cohort,2 13% in an
Italian cohort,3 and 22.5% in a North American cohort.5
The apparent severity of NMO in the North American
cohort may be related to the following: (1) the high pro-
portion of untreated patients in 1999,when the newNMO
spectrum was first described; (2) a selection bias for se-
vere hospitalized cases; and (3) the unspecified propor-
tion of nonwhite patients in this population. The severe
disability in our FWI cohort was mainly because of early
and severe vision impairment, characterized by a per-
manent loss of vision after 2 attacks in a given eye and
by a median time of 2 years from onset to monocular vi-
sion loss.6 Nevertheless, some patients in the FWI co-
hort experienced complete regression of their myelitis
and remained fully ambulatory. These data raise ques-
tions about the validity of the vision scale used to calcu-
late the EDSS score when applied to patients with NMO.
Several biases may limit interpretation of our study
results. First, we may have inadvertently selected pa-
tients with good prognosis in the MF cohort, as demon-
strated by the low proportion of deaths compared with
that in the FWI cohort. This could have occurred be-
cause of selection bias, as all patients in the MF cohort
were being followed up at the start of the study and the
2006 NMO criteria were used in this population. In con-
trast to the 1999 NMO criteria used in the FWI cohort,
the 2006NMO criteria do not include the severity of mo-
tor disability and vision impairment in the diagnosis and
may select less disabled patients.23 Second, whereas the
collected data among this NMO cohort were among the
most complete in the literature, the retrospective study
design induced a lack of power in the search for predic-
tive factors of disability. For example, good recovery af-
ter the first clinical event reported among patients with
go-NMO cannot be compared with that among patients
of the entire MF and FWI cohorts because of the wide
range of treatments used after the first event, as well as
the difficulty of assessing this in patients with a 10-year
follow-up period. Third, the definition used for go-
NMO was derived from that used for MS. Visual acuity
was included in the EDSS score, and a converted vision
score of 3 was compatible with a maximum VA of 0.1 or
worse (20/200 Snellen) in the worse eye, which raises
questions about whether symptoms were benign. That
is why we also considered an EDSS score of 2 compat-
ible with a large scotoma or a maximum VA of 0.33 to
Table 2. Characteristics of Patients Having Neuromyelitis Optica (NMO) in Metropolitan France (MF) and in the French West Indies
(FWI) and of Patients Having Benign Multiple Sclerosis (MS) in Alsace and in the FWIa
Characteristic
NMO
in FWI
(n=50)
Standard
NMO in MF
(n=81)
go-NMO
in MF
(n=11)
P
Valueb
Benign MS
in Alsace
(n=232)
P
Valuec
Benign MS
in FWI
(n=27)
P
Valued
Female-male ratio 9:1 2.5:1 1.75:1 .85 2.8:1 .70 8:1 .13
White-nonwhite ratio 0:50 9:1 4.5:1 .79 28:1 .10 0:27 .01
Age at onset, mean (SD), y 31.8 (13.0) 35.2 (14.0) 31.6 (12.6) .36 29.4 (8.7) .71 26.3 (8.9) .13
Disease course monophasic:remitting ratio 0:50 1:4 1:10 .66 0:232 .03 0:27 .01
Time from onset to second attack,
mean (SD), mo
23.3 (45.0) 31.2 (44.6) 46.5 (40.2) .08 59.5 (32.7) .17 58.9 (64.2) .17
Annualized relapse rate, mean (SD), mo 0.9 (0.7) 1.0 (1.5) 0.3 (0.1) .01 0.4 (0.2) .24 0.4 (0.2) .19
Patients receiving treatments, No. (%) 39 (78.0) 76 (93.8) 8 (72.7) .08 181 (78.0) .97 20 (74.0) .82
No. of treatments received, mean . . . . . . . . . .06 . . . .01 . . . .31
IM 1 3 2 . . . 148 . . . 19 . . .
IS 30 48 4 . . . 7 . . . 0 . . .
IMIS 8 25 2 . . . 26 . . . 1 . . .
Time to first treatment,
median (95% CI), y
4.5 (2.3-6.7) 2.1 (1.4-2.7) 12.0 (8.3-15.7) .03 11.0 (5.0-17.0) .65 11.0 (9.6-12.4) .50
NMO-IgG, No. (%) 15 (62.5) (n=24) 34 (50.0) (n=68) 6 (54.5) .96 . . . . . . . . . . . .
Abbreviations: CI, confidence interval; ellipsis, not applicable; go-NMO, NMO with a good outcome; IM, immunomodulatory treatment; IS, immunosuppressive
treatment.
aPatients with an Expanded Disability Status Scale score lower than 3 and with less than 10 years’ follow-up are excluded.
bComparison between NMO subgroups in MF.
cComparison between go-NMO and benign MS in Alsace.
dComparison between benign MS in Alsace and in the FWI.
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0.2 (20/60 to 20/100 Snellen) in the worse eye. How-
ever, such considerations do not alter the results of the
study.
Because a disabling attack may occur after a long fol-
low-up period, a benign form of NMO cannot be de-
fined. However, results of this study show that go-NMO
exists. This finding is applicable to a small percentage of
patients with NMO descended from white populations
with a low annualized relapse rate of NMO. The result
is independent of NMO-IgG seropositivity, which does
not affect the course of NMO.1,2,16,22 As inMS, a long first
interattack interval could be indicative of a less dis-
abling course of NMO.24 Furthermore, the resolution of
myelitis without sequelae on MR imaging (spontane-
ously or after a short course of oral corticotherapy) may
suggest a potentially good outcome ofNMO.WhenNMO
is suspected, complete regression of symptoms and of sig-
nal abnormalities onMR imaging may also be indicative
of a good outcome. These considerations are valid only
in the absence of the predictors of severity mentioned
herein.
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